Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mavodelpar (REN001), a selective PPARδ agonist, effectively suppresses glomerular injury and renal fibrosis. It is utilized in the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,670.00 | |
50 mg | 6-8 weeks | $ 2,180.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | Mavodelpar (REN001), a selective PPARδ agonist, effectively suppresses glomerular injury and renal fibrosis. It is utilized in the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). |
Synonyms | HPP593, REN001, REN001 ; HPP593 |
Molecular Weight | 537.55 |
Formula | C31H29FNNaO5 |
CAS No. | 1604815-32-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mavodelpar 1604815-32-8 HPP593 HPP-593 HPP 593 REN001 ; HPP-593 REN-001 REN001 REN 001 REN001 ; HPP593 REN001 ; HPP593 REN001 ; HPP 593 inhibitor inhibit